Why BiondVax Pharmaceuticals Stock Imploded Today

Why BiondVax Pharmaceuticals Stock Imploded Today

Investors sold off shares of the biopharmaceutical company after it reported negative results from a phase 3 clinical trial. BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and severity.